Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · IEX Real-Time Price · USD
5.21
+0.05 (0.97%)
At close: Apr 24, 2024, 4:00 PM
5.13
-0.08 (-1.54%)
After-hours: Apr 24, 2024, 4:30 PM EDT

Foghorn Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018
Revenue
34.1619.231.320.4300
Revenue Growth (YoY)
77.63%1357.77%206.74%---
Gross Profit
34.1619.231.320.4300
Selling, General & Admin
32.3730.7521.7311.256.724.82
Research & Development
109.69105.6280.3357.7244.3621.23
Operating Expenses
142.06136.37102.0568.9651.0826.05
Operating Income
-107.91-117.14-100.73-68.53-51.08-26.05
Interest Expense / Income
001.910.980.540.48
Other Expense / Income
-13.71-8.26-1.32-0.71-0.5-0.2
Pretax Income
-94.2-108.88-101.32-68.8-51.13-26.34
Income Tax
4.2300000
Net Income
-98.43-108.88-101.32-68.8-51.13-26.34
Shares Outstanding (Basic)
4242371143
Shares Outstanding (Diluted)
4242371143
Shares Change
0.92%11.89%236.49%163.53%42.23%-
EPS (Basic)
-2.34-2.62-2.73-6.23-12.20-8.94
EPS (Diluted)
-2.34-2.62-2.73-6.23-12.20-8.94
Free Cash Flow
-119.33192.4-53.56-47.22-47.3-24.19
Free Cash Flow Per Share
-2.844.63-1.44-4.27-11.28-8.21
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-315.93%-609.20%-7637.15%-15937.44%--
Profit Margin
-288.17%-566.27%-7681.58%-16000.00%--
Free Cash Flow Margin
-349.38%1000.63%-4060.88%-10981.16%--
EBITDA
-85.54-100.98-91.9-62.29-48.8-25.47
EBITDA Margin
-250.44%-525.18%-6967.32%-14486.74%--
Depreciation & Amortization
8.667.97.525.531.790.38
EBIT
-94.2-108.88-99.41-67.82-50.59-25.85
EBIT Margin
-275.80%-566.27%-7537.07%-15772.33%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).